Back to Search
BETH THURBERG, M.D.
M.D.
Anatomic Pathology Physician
NPI: 1801820634Individual
Specialties, Licenses & Credentials
Anatomic Pathology PhysicianPrimary
Pathology — Anatomic Pathology
Code: 207ZP0101X
160799(MA)
Research & Publications (20)
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
PMID 18538603·Mol Genet Metab·2008
4-observational
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.
PMID 17075580·Lab Invest·2006
5-case
Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
PMID 19414635·Circulation·2009
4-observational
Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
PMID 15102080·J Invest Dermatol·2004
3-trial
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
PMID 12427118·Kidney Int·2002
3-trial
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
PMID 19521244·Genet Med·2009
3-trial
Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues.
PMID 19406991·Am J Pathol·2009
7-preclinical
Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
PMID 19265719·Genet Med·2009
3-trial
Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.
PMID 19231265·Mol Genet Metab·2009
7-preclinical
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
PMID 19010839·Clin Cancer Res·2008
7-preclinical
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.
PMID 18648322·J Neuropathol Exp Neurol·2008
7-preclinical
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
PMID 18067019·Leuk Lymphoma·2007
8-other
Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
PMID 17572127·Mol Genet Metab·2007
7-preclinical
Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.
PMID 17510371·J Histochem Cytochem·2007
7-preclinical
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
PMID 17151339·Neurology·2007
4-observational
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
PMID 16860134·J Pediatr·2006
3-trial
Mice with elevated muscle glycogen stores do not have improved exercise performance.
PMID 15850786·Biochem Biophys Res Commun·2005
7-preclinical
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
PMID 15839836·Biochem J·2005
7-preclinical
Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise.
PMID 15711014·J Biol Chem·2005
7-preclinical
High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology.
PMID 15637339·J Histochem Cytochem·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- GENZYME CORPORATION, ONE MOUNTAIN ROAD
FRAMINGHAM, MA 01701 - Phone
- (508) 271-2739
Quick Facts
- NPI
- 1801820634
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile